Antitumor peptide immune checkpoint inhibitors
Time of Update: 2022-11-15
Inhalation is not equal to nasal spray, what is the difference between the two vaccination methods?【Route of administration】Gastrointestinal administration and lung administrationAnalysis of the latest patent layout of key PI3K inhibitorsOrphan Drug Development: Shelter the World for Patients with Rare Diseases【Route of administration inventory】Ocular administrationClick "Read Original" to keep abreast of industry trendsCTLA-4 or CTLA4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152, is a protein receptor that acts as an immune checkpoint and downregulates the immune response.
Lilly CIIE joined hands with Ader Biologics and Ranshi Medical to help the new development of precision diagnosis and treatment of cancer in China
Time of Update: 2022-11-14
On November 6, at the 5th CIIE, Lilly reached a cooperation intention with Ader Biologics and Ranshi Medical to jointly promote the development of Lilly's world's first highly selective RET inhibitor, septitinib, for companion diagnostics in China, so as to benefit more RET-driven cancer patients in China.
Will the eighth batch of collective procurement include biosimilars? 180 companies compete for the 10 billion market
Time of Update: 2022-10-25
With the end of the seventh batch of collective procurement, the eighth batch of collective procurement has become a hot topic in the industry. Among them, the widely concerned "biological drug colle
The CXO sector continues to be booming, with more than 90% of stocks rising by more than 10
Time of Update: 2022-05-04
It is reported that this time Jiuzhou Pharmaceutical intends to increase the capital of Siwei Pharmaceutical by 30 million yuan, the main body of the “Zhejiang Siwei Pharmaceutical Technology Co.
Encapsulating innovative therapies such as trispecific cytokine inhibitors and cutting-edge immune-inflammatory diseases
Time of Update: 2022-05-01
Bioniz's lead product candidates are multispecific inhibitors that simultaneously target multiple clinically validated disease-driving cytokines, including potential "first-in-class" therapies BNZ-1 and BNZ-2 in clinical development, aimed at Addressing unmet needs in a range of immuno-inflammatory indications .
FDA Accepts New Drug Application for Mirati's KRAS Inhibitor
Time of Update: 2022-03-06
S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for the KRAS G12C inhibitor adagrasib, for the treatment of patients with KRAS G12C mutation non-small cell lung cancer (NSCLC) .
The application for registration of new anticancer drug of Haite Biotech has been accepted
Time of Update: 2022-02-24
CPT is a new recombinant protein targeting anti-tumor drug developed by its joint-stock subsidiary Beijing Shadong Biotechnology Co.
Phase III clinical trials have shown that CPT combined with TD regimen in the treatment of relapsed and refractory multiple myeloma can significantly improve the progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) of patients.
Annual inventory of 2021 acute lymphoblastic leukemia research progress summary
Time of Update: 2022-01-25
When medical insurance is in progress | Care for ALL: Belintoumumab helps patients with relapsed or refractory acute lymphoblastic leukemia to open the era of immunotherapy 03 Antibody-drug conjugates (ADC) 1.
Voriconazole tablets, a subsidiary of Jingfeng Pharmaceuticals, obtained the drug registration certificate
Time of Update: 2021-11-05
In addition, voriconazole also has a bactericidal effect against other pathogenic fungi in vitro, including bacteria that are less sensitive to current antifungal drugs, such as Actinomyces and Fusarium .
Tribute 2021| Build China's Pharmaceutical Innovation Ecosystem - The first in a series of reports: 2015-2020 Development Review and Future Outlook" was officially released
Time of Update: 2021-03-23
202132，（PhIRDA）（RDPAC），《——：2015-2020》（“”）。《》，、、（、）、，，，、，。，“”（），《》。 2020 is the final year of the major scientific and technological projects of "Major New Drug Development"; 2021 is the beginning yea
Weak epidemic prevention, a number of pharmacies were fined and closed
Time of Update: 2021-01-24
Case I: Xinhua District You'an University Pharmacy sales of goods not clearly marked price case January 6, according to reports from the masses, Xinhua District Market Supervision Bureau in accordance with the law to Shijiazhuang You'anDa Pharmacy inspection.
How to conduct non-clinical research on cloud-based cell therapy products
Time of Update: 2021-01-21
, cell therapy products have their particularity, in the development process can not be carried out in full accordance with the idea of small molecular compounds, to the traditional non-clinical research methods put forward a huge challenge.
Deki Pharmaceuticals Selinexor's three treatments were selected for the latest edition of NCCN Guidelines ®
Time of Update: 2020-12-26
"Recently, the NCCN® multiple myeloma guidelines were updated to the fourth edition of 2021, and several options for selinexor have been included in the latest version of the recommendation guidelines," said Professor Qiu Yugui of the Hospital of Hematology of the Chinese Academy of Medical Sciences.
The shortest is only 29 days! Medical device innovation approval and priority approval of large inventory
Time of Update: 2020-10-27
The two major procedures are the "green channel" of medical device approval opened by the State Drug Administration based on encouraging medical device research and development innovation and meeting the demands of clinical urgent needs, which greatly shortens the time-to-market of products by priority arrangements for review, speeding up the efficiency of review and approval, and ensuring that the corresponding products and results can be applied to clinical practice as soon as possible.
Bridgewest Australia Holdings LLC acquires Pfizer manufacturing facilities
Time of Update: 2020-09-23
the Adelaide facility has manufacturing capabilities, staff expertise and support systems to manufacture and test microbial-based products at the cGMP (Dynamic Drug Production Management Practice) level, covering proteins, vaccines and protons from development to commercialization.